Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Rectal Neoplasms | 47 | 2025 | 1185 | 6.440 |
Why?
|
Pancreatic Neoplasms | 74 | 2024 | 5443 | 6.080 |
Why?
|
Neoadjuvant Therapy | 55 | 2025 | 2909 | 4.310 |
Why?
|
Liver Neoplasms | 47 | 2024 | 4360 | 4.290 |
Why?
|
Adenocarcinoma | 56 | 2025 | 6404 | 3.790 |
Why?
|
Carcinoma, Hepatocellular | 26 | 2023 | 2331 | 3.740 |
Why?
|
Fluorouracil | 41 | 2024 | 1655 | 3.390 |
Why?
|
Bile Duct Neoplasms | 17 | 2024 | 616 | 3.180 |
Why?
|
Cholangiocarcinoma | 17 | 2024 | 562 | 3.180 |
Why?
|
Carcinoma, Pancreatic Ductal | 29 | 2024 | 1756 | 3.110 |
Why?
|
Radiotherapy, Intensity-Modulated | 22 | 2023 | 811 | 2.460 |
Why?
|
Esophageal Neoplasms | 23 | 2023 | 1675 | 2.460 |
Why?
|
Stomach Neoplasms | 20 | 2021 | 1481 | 2.370 |
Why?
|
Radiotherapy Planning, Computer-Assisted | 24 | 2021 | 1679 | 2.340 |
Why?
|
Anus Neoplasms | 13 | 2021 | 337 | 2.220 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 53 | 2024 | 11854 | 2.040 |
Why?
|
Radiosurgery | 13 | 2024 | 1346 | 1.810 |
Why?
|
Radiotherapy Dosage | 35 | 2023 | 2920 | 1.770 |
Why?
|
Esophagogastric Junction | 11 | 2023 | 349 | 1.590 |
Why?
|
Leucovorin | 20 | 2024 | 643 | 1.570 |
Why?
|
Neoplasm Recurrence, Local | 29 | 2023 | 9433 | 1.540 |
Why?
|
Deoxycytidine | 12 | 2019 | 887 | 1.470 |
Why?
|
Combined Modality Therapy | 41 | 2023 | 8562 | 1.320 |
Why?
|
Gastrointestinal Neoplasms | 8 | 2023 | 959 | 1.280 |
Why?
|
Radiotherapy, Conformal | 10 | 2016 | 549 | 1.190 |
Why?
|
Carcinoma, Squamous Cell | 13 | 2021 | 4069 | 1.130 |
Why?
|
Photons | 5 | 2019 | 594 | 1.130 |
Why?
|
Neoplasm Staging | 49 | 2024 | 11254 | 1.120 |
Why?
|
Lymphopenia | 6 | 2025 | 298 | 1.070 |
Why?
|
Tumor Burden | 13 | 2018 | 1913 | 0.990 |
Why?
|
Intraoperative Care | 3 | 2019 | 771 | 0.920 |
Why?
|
Radiotherapy, Adjuvant | 14 | 2022 | 1794 | 0.900 |
Why?
|
Colorectal Neoplasms | 16 | 2022 | 6969 | 0.850 |
Why?
|
Biliary Tract Neoplasms | 3 | 2020 | 187 | 0.830 |
Why?
|
Organoplatinum Compounds | 7 | 2024 | 408 | 0.820 |
Why?
|
Aged | 125 | 2025 | 171544 | 0.820 |
Why?
|
Humans | 288 | 2025 | 768298 | 0.790 |
Why?
|
Survival Rate | 34 | 2024 | 12870 | 0.770 |
Why?
|
Antimetabolites, Antineoplastic | 3 | 2014 | 646 | 0.760 |
Why?
|
Colonic Neoplasms | 8 | 2024 | 2542 | 0.750 |
Why?
|
Middle Aged | 131 | 2025 | 223463 | 0.750 |
Why?
|
Gene Amplification | 4 | 2020 | 1090 | 0.740 |
Why?
|
Radiodermatitis | 2 | 2019 | 61 | 0.740 |
Why?
|
Radiotherapy | 11 | 2021 | 1509 | 0.720 |
Why?
|
Male | 158 | 2025 | 364870 | 0.700 |
Why?
|
Chemotherapy, Adjuvant | 20 | 2022 | 3553 | 0.690 |
Why?
|
Prognosis | 42 | 2025 | 30020 | 0.680 |
Why?
|
Retrospective Studies | 80 | 2025 | 81768 | 0.660 |
Why?
|
Radiation-Sensitizing Agents | 8 | 2021 | 349 | 0.660 |
Why?
|
Aged, 80 and over | 61 | 2024 | 59683 | 0.660 |
Why?
|
Radiation Oncology | 8 | 2023 | 572 | 0.650 |
Why?
|
Organs at Risk | 5 | 2020 | 368 | 0.650 |
Why?
|
Radiation Injuries | 8 | 2020 | 1204 | 0.620 |
Why?
|
Losartan | 2 | 2023 | 263 | 0.620 |
Why?
|
Female | 151 | 2025 | 397050 | 0.620 |
Why?
|
Laparotomy | 2 | 2018 | 458 | 0.610 |
Why?
|
Head and Neck Neoplasms | 6 | 2015 | 2923 | 0.610 |
Why?
|
Disease-Free Survival | 18 | 2024 | 6856 | 0.600 |
Why?
|
Feasibility Studies | 10 | 2023 | 5311 | 0.600 |
Why?
|
Fluorodeoxyglucose F18 | 7 | 2022 | 2056 | 0.590 |
Why?
|
Intestine, Small | 3 | 2013 | 1218 | 0.580 |
Why?
|
Radiation Tolerance | 7 | 2019 | 478 | 0.570 |
Why?
|
Treatment Outcome | 42 | 2024 | 65365 | 0.540 |
Why?
|
Liver Failure | 1 | 2019 | 252 | 0.540 |
Why?
|
Lymph Nodes | 6 | 2019 | 3471 | 0.530 |
Why?
|
Cholecystitis | 1 | 2017 | 181 | 0.520 |
Why?
|
Pancreatectomy | 7 | 2023 | 823 | 0.510 |
Why?
|
Gastrectomy | 7 | 2020 | 696 | 0.500 |
Why?
|
Camptothecin | 5 | 2017 | 593 | 0.500 |
Why?
|
Gastrointestinal Diseases | 3 | 2019 | 1207 | 0.490 |
Why?
|
Gallbladder | 1 | 2017 | 308 | 0.490 |
Why?
|
Positron-Emission Tomography | 15 | 2024 | 6670 | 0.490 |
Why?
|
Protons | 6 | 2023 | 1112 | 0.490 |
Why?
|
Lymphatic Metastasis | 13 | 2018 | 2924 | 0.480 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 10 | 2019 | 1765 | 0.460 |
Why?
|
Neuroectodermal Tumors, Primitive | 2 | 2005 | 137 | 0.450 |
Why?
|
Respiration | 4 | 2013 | 1667 | 0.430 |
Why?
|
Arteriovenous Shunt, Surgical | 1 | 2016 | 291 | 0.430 |
Why?
|
Portal Vein | 2 | 2023 | 431 | 0.430 |
Why?
|
Follow-Up Studies | 22 | 2024 | 39405 | 0.420 |
Why?
|
Brachytherapy | 3 | 2019 | 1226 | 0.420 |
Why?
|
Neoplasm, Residual | 5 | 2021 | 1019 | 0.410 |
Why?
|
Blood Vessels | 1 | 2018 | 1110 | 0.410 |
Why?
|
Ketamine | 1 | 2018 | 524 | 0.400 |
Why?
|
Mitomycin | 5 | 2019 | 262 | 0.400 |
Why?
|
Kaplan-Meier Estimate | 14 | 2025 | 6541 | 0.390 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2016 | 1126 | 0.390 |
Why?
|
Proto-Oncogene Proteins B-raf | 5 | 2019 | 2058 | 0.390 |
Why?
|
Dose-Response Relationship, Radiation | 6 | 2018 | 881 | 0.390 |
Why?
|
Receptor, erbB-2 | 2 | 2022 | 2588 | 0.390 |
Why?
|
Adult | 71 | 2025 | 223622 | 0.380 |
Why?
|
Molecular Targeted Therapy | 7 | 2021 | 2830 | 0.380 |
Why?
|
Autophagy | 2 | 2018 | 1350 | 0.370 |
Why?
|
Bile Ducts, Intrahepatic | 5 | 2015 | 304 | 0.360 |
Why?
|
Antineoplastic Agents | 19 | 2020 | 13696 | 0.360 |
Why?
|
Surgical Mesh | 1 | 2013 | 290 | 0.350 |
Why?
|
Papillomaviridae | 1 | 2016 | 1140 | 0.350 |
Why?
|
Hypoglycemic Agents | 3 | 2014 | 3108 | 0.350 |
Why?
|
Astrocytes | 1 | 2018 | 1349 | 0.350 |
Why?
|
Prospective Studies | 24 | 2024 | 54921 | 0.350 |
Why?
|
Aluminum Oxide | 1 | 2009 | 41 | 0.340 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 526 | 0.340 |
Why?
|
Electrochemistry | 1 | 2009 | 146 | 0.340 |
Why?
|
Thrombosis | 2 | 2023 | 2955 | 0.340 |
Why?
|
Radiation Protection | 1 | 2013 | 428 | 0.330 |
Why?
|
Relative Biological Effectiveness | 3 | 2018 | 313 | 0.330 |
Why?
|
Spine | 1 | 2016 | 1141 | 0.330 |
Why?
|
Proto-Oncogene Proteins c-met | 3 | 2020 | 567 | 0.330 |
Why?
|
Neoplasm Invasiveness | 7 | 2023 | 3631 | 0.320 |
Why?
|
Silicon | 1 | 2009 | 143 | 0.320 |
Why?
|
Prostatic Neoplasms | 6 | 2016 | 11220 | 0.320 |
Why?
|
Neoplasms, Second Primary | 1 | 2016 | 1060 | 0.310 |
Why?
|
Microelectrodes | 1 | 2009 | 308 | 0.310 |
Why?
|
Pancreaticoduodenectomy | 4 | 2019 | 516 | 0.310 |
Why?
|
Models, Statistical | 3 | 2020 | 5099 | 0.300 |
Why?
|
Consensus | 5 | 2020 | 3212 | 0.300 |
Why?
|
Lighting | 1 | 2009 | 210 | 0.290 |
Why?
|
Radiometry | 3 | 2020 | 816 | 0.290 |
Why?
|
Radiotherapy, Computer-Assisted | 1 | 2007 | 90 | 0.290 |
Why?
|
Rectum | 6 | 2023 | 900 | 0.270 |
Why?
|
Mutation | 16 | 2020 | 30230 | 0.270 |
Why?
|
ras Proteins | 5 | 2014 | 1058 | 0.270 |
Why?
|
Supratentorial Neoplasms | 2 | 2005 | 159 | 0.270 |
Why?
|
Colon | 2 | 2020 | 1805 | 0.270 |
Why?
|
Magnetic Resonance Imaging | 17 | 2024 | 36849 | 0.270 |
Why?
|
Drug Resistance, Neoplasm | 8 | 2024 | 5335 | 0.260 |
Why?
|
Antibodies, Monoclonal | 6 | 2021 | 9261 | 0.260 |
Why?
|
Tomography, Spiral Computed | 1 | 2007 | 274 | 0.260 |
Why?
|
Hepatectomy | 2 | 2020 | 588 | 0.250 |
Why?
|
Neuroendocrine Tumors | 1 | 2012 | 657 | 0.250 |
Why?
|
Biological Products | 2 | 2019 | 934 | 0.250 |
Why?
|
DNA Mutational Analysis | 1 | 2014 | 4120 | 0.250 |
Why?
|
Palliative Care | 2 | 2020 | 3643 | 0.250 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2014 | 2461 | 0.250 |
Why?
|
Anal Canal | 4 | 2021 | 376 | 0.240 |
Why?
|
Esophagectomy | 4 | 2017 | 482 | 0.240 |
Why?
|
Lung Neoplasms | 7 | 2019 | 13576 | 0.240 |
Why?
|
Cisplatin | 5 | 2023 | 1661 | 0.240 |
Why?
|
Survival Analysis | 9 | 2019 | 10117 | 0.240 |
Why?
|
Tumor Microenvironment | 6 | 2024 | 3940 | 0.240 |
Why?
|
Tomography, X-Ray Computed | 16 | 2021 | 20766 | 0.240 |
Why?
|
Venous Thrombosis | 1 | 2014 | 1317 | 0.240 |
Why?
|
Carcinoma | 1 | 2016 | 2340 | 0.240 |
Why?
|
Nanostructures | 1 | 2009 | 553 | 0.240 |
Why?
|
Parotid Gland | 1 | 2005 | 178 | 0.230 |
Why?
|
Nanotechnology | 1 | 2009 | 714 | 0.230 |
Why?
|
Spinal Neoplasms | 1 | 2010 | 716 | 0.220 |
Why?
|
Immunotherapy | 7 | 2023 | 4740 | 0.220 |
Why?
|
Brain Neoplasms | 3 | 2018 | 9197 | 0.220 |
Why?
|
Pelvis | 5 | 2020 | 738 | 0.220 |
Why?
|
Adenomatous Polyposis Coli Protein | 2 | 2014 | 182 | 0.210 |
Why?
|
Gallbladder Neoplasms | 2 | 2018 | 191 | 0.210 |
Why?
|
Treatment Failure | 5 | 2019 | 2664 | 0.210 |
Why?
|
Esthetics, Dental | 2 | 2022 | 269 | 0.210 |
Why?
|
Carboplatin | 3 | 2022 | 799 | 0.200 |
Why?
|
Proportional Hazards Models | 9 | 2021 | 12557 | 0.200 |
Why?
|
Patient Selection | 6 | 2023 | 4265 | 0.200 |
Why?
|
Phosphatidylinositol 3-Kinases | 4 | 2016 | 2884 | 0.200 |
Why?
|
Neoplasms | 9 | 2023 | 22389 | 0.200 |
Why?
|
GTP Phosphohydrolases | 3 | 2014 | 525 | 0.200 |
Why?
|
Contrast Media | 1 | 2015 | 5337 | 0.200 |
Why?
|
CA-19-9 Antigen | 3 | 2022 | 107 | 0.200 |
Why?
|
Salvage Therapy | 3 | 2020 | 1277 | 0.200 |
Why?
|
Cerebral Cortex | 1 | 2018 | 5830 | 0.200 |
Why?
|
Maxilla | 2 | 2022 | 489 | 0.200 |
Why?
|
Lymphatic Irradiation | 3 | 2010 | 115 | 0.200 |
Why?
|
Radiography | 6 | 2013 | 6993 | 0.190 |
Why?
|
Pilot Projects | 3 | 2021 | 8730 | 0.190 |
Why?
|
Quality of Life | 9 | 2024 | 13499 | 0.190 |
Why?
|
RNA-Directed DNA Polymerase | 1 | 2022 | 223 | 0.190 |
Why?
|
Peritoneal Neoplasms | 2 | 2022 | 715 | 0.190 |
Why?
|
Carcinoembryonic Antigen | 2 | 2014 | 338 | 0.190 |
Why?
|
Diarrhea | 3 | 2015 | 1320 | 0.190 |
Why?
|
Medical Illustration | 2 | 2015 | 135 | 0.190 |
Why?
|
Disease Progression | 9 | 2022 | 13646 | 0.190 |
Why?
|
Microsatellite Instability | 2 | 2016 | 726 | 0.190 |
Why?
|
Collagen Type I | 1 | 2024 | 620 | 0.180 |
Why?
|
Proto-Oncogene Proteins | 6 | 2014 | 4526 | 0.180 |
Why?
|
Nerve Tissue | 1 | 2021 | 78 | 0.180 |
Why?
|
Patient Participation | 1 | 2010 | 1448 | 0.180 |
Why?
|
Standard of Care | 3 | 2022 | 570 | 0.180 |
Why?
|
Cell Line, Tumor | 13 | 2024 | 17132 | 0.180 |
Why?
|
Duodenum | 1 | 2023 | 495 | 0.180 |
Why?
|
Rotavirus | 1 | 2001 | 110 | 0.180 |
Why?
|
Metformin | 1 | 2008 | 911 | 0.170 |
Why?
|
Dinoprostone | 1 | 2023 | 597 | 0.170 |
Why?
|
Massachusetts | 4 | 2020 | 8902 | 0.170 |
Why?
|
HMGA2 Protein | 1 | 2020 | 101 | 0.170 |
Why?
|
Tumor Suppressor Protein p53 | 5 | 2022 | 2950 | 0.170 |
Why?
|
Drug Administration Schedule | 3 | 2021 | 4859 | 0.170 |
Why?
|
Microsatellite Repeats | 1 | 2021 | 784 | 0.160 |
Why?
|
Radiation Dosage | 3 | 2017 | 1973 | 0.160 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2000 | 353 | 0.160 |
Why?
|
Colostomy | 1 | 2019 | 104 | 0.160 |
Why?
|
Mice, Nude | 4 | 2024 | 3630 | 0.150 |
Why?
|
Preoperative Period | 2 | 2022 | 563 | 0.150 |
Why?
|
Isocitrate Dehydrogenase | 2 | 2015 | 954 | 0.150 |
Why?
|
Liver | 5 | 2022 | 7570 | 0.150 |
Why?
|
Bilirubin | 1 | 2020 | 438 | 0.150 |
Why?
|
Paclitaxel | 3 | 2022 | 1736 | 0.150 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2019 | 117 | 0.150 |
Why?
|
Capsid Proteins | 1 | 2001 | 468 | 0.150 |
Why?
|
Movement | 3 | 2011 | 1490 | 0.150 |
Why?
|
Stomach | 3 | 2013 | 703 | 0.150 |
Why?
|
Hydrogels | 1 | 2023 | 744 | 0.150 |
Why?
|
Hepadnaviridae | 1 | 2017 | 1 | 0.150 |
Why?
|
I-kappa B Proteins | 1 | 2018 | 210 | 0.150 |
Why?
|
Sheep | 1 | 2000 | 1451 | 0.150 |
Why?
|
Diabetes Mellitus, Type 2 | 3 | 2014 | 12239 | 0.150 |
Why?
|
Models, Biological | 4 | 2018 | 9494 | 0.150 |
Why?
|
Gene Expression Profiling | 5 | 2024 | 9508 | 0.150 |
Why?
|
Disulfiram | 1 | 2017 | 63 | 0.140 |
Why?
|
Antigens, Viral | 1 | 2001 | 992 | 0.140 |
Why?
|
Gene Expression Regulation, Neoplastic | 7 | 2024 | 8628 | 0.140 |
Why?
|
Colonoscopy | 2 | 2016 | 1412 | 0.140 |
Why?
|
Preoperative Care | 4 | 2015 | 2257 | 0.140 |
Why?
|
Conus Snail | 1 | 2016 | 7 | 0.140 |
Why?
|
Neurosciences | 1 | 2022 | 385 | 0.140 |
Why?
|
Pelvic Bones | 2 | 2017 | 274 | 0.140 |
Why?
|
Algorithms | 6 | 2015 | 14154 | 0.140 |
Why?
|
Serum Albumin | 1 | 2020 | 676 | 0.140 |
Why?
|
Hepatitis, Viral, Human | 1 | 2017 | 141 | 0.140 |
Why?
|
Angiotensins | 1 | 2017 | 141 | 0.140 |
Why?
|
Cauda Equina | 1 | 2016 | 45 | 0.140 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2020 | 2524 | 0.130 |
Why?
|
Societies, Scientific | 1 | 2017 | 223 | 0.130 |
Why?
|
DNA, Neoplasm | 2 | 2019 | 1748 | 0.130 |
Why?
|
Epirubicin | 1 | 2016 | 81 | 0.130 |
Why?
|
Pulmonary Valve | 1 | 2000 | 413 | 0.130 |
Why?
|
Drug Screening Assays, Antitumor | 2 | 2019 | 720 | 0.130 |
Why?
|
Glial Fibrillary Acidic Protein | 1 | 2018 | 559 | 0.130 |
Why?
|
Fiducial Markers | 2 | 2015 | 134 | 0.130 |
Why?
|
Peritoneum | 1 | 2017 | 228 | 0.130 |
Why?
|
Software | 2 | 2017 | 4452 | 0.130 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2018 | 174 | 0.130 |
Why?
|
Genetic Heterogeneity | 2 | 2019 | 737 | 0.130 |
Why?
|
Practice Guidelines as Topic | 5 | 2022 | 7453 | 0.130 |
Why?
|
Radiopharmaceuticals | 5 | 2024 | 2734 | 0.130 |
Why?
|
Recombinases | 1 | 2016 | 69 | 0.130 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 3 | 2016 | 906 | 0.130 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 3 | 2017 | 5422 | 0.130 |
Why?
|
Decision Support Techniques | 2 | 2018 | 2005 | 0.130 |
Why?
|
Hospitals, General | 1 | 2020 | 807 | 0.130 |
Why?
|
Cholelithiasis | 1 | 2017 | 408 | 0.120 |
Why?
|
Karyopherins | 1 | 2015 | 134 | 0.120 |
Why?
|
Osteopontin | 1 | 2017 | 306 | 0.120 |
Why?
|
Bone Marrow Diseases | 1 | 2017 | 234 | 0.120 |
Why?
|
Animals | 23 | 2024 | 169322 | 0.120 |
Why?
|
DNA Breaks, Double-Stranded | 2 | 2019 | 615 | 0.120 |
Why?
|
Apoptosis | 4 | 2018 | 9506 | 0.120 |
Why?
|
Dura Mater | 1 | 2016 | 297 | 0.120 |
Why?
|
Neutropenia | 2 | 2017 | 893 | 0.120 |
Why?
|
Informed Consent | 1 | 2021 | 1010 | 0.120 |
Why?
|
Lymph Node Excision | 5 | 2016 | 1274 | 0.120 |
Why?
|
Neural Tube Defects | 1 | 2016 | 255 | 0.120 |
Why?
|
Cecal Neoplasms | 1 | 2014 | 27 | 0.120 |
Why?
|
Receptors, CXCR | 1 | 2014 | 52 | 0.110 |
Why?
|
Chromones | 1 | 2014 | 148 | 0.110 |
Why?
|
MAP Kinase Kinase 1 | 1 | 2015 | 331 | 0.110 |
Why?
|
Fibromatosis, Aggressive | 1 | 2015 | 125 | 0.110 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2020 | 10377 | 0.110 |
Why?
|
Urogenital System | 2 | 2010 | 88 | 0.110 |
Why?
|
Community Health Centers | 1 | 2017 | 469 | 0.110 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2019 | 755 | 0.110 |
Why?
|
Four-Dimensional Computed Tomography | 2 | 2011 | 141 | 0.110 |
Why?
|
Dental Implants | 1 | 2022 | 807 | 0.110 |
Why?
|
Postoperative Period | 2 | 2016 | 1830 | 0.110 |
Why?
|
Abdominal Neoplasms | 1 | 2015 | 287 | 0.110 |
Why?
|
Arthroplasty, Replacement, Ankle | 1 | 2013 | 26 | 0.110 |
Why?
|
Receptors, Glucagon | 1 | 2013 | 90 | 0.110 |
Why?
|
Signal Transduction | 3 | 2024 | 23629 | 0.110 |
Why?
|
Diabetes Mellitus | 2 | 2023 | 5890 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 957 | 0.110 |
Why?
|
Arteriovenous Fistula | 1 | 2016 | 320 | 0.110 |
Why?
|
Enzyme Inhibitors | 2 | 2014 | 3722 | 0.110 |
Why?
|
Small Molecule Libraries | 1 | 2019 | 743 | 0.110 |
Why?
|
Doxorubicin | 1 | 2020 | 2229 | 0.110 |
Why?
|
Injections, Intravenous | 1 | 2015 | 1378 | 0.110 |
Why?
|
Endonucleases | 1 | 2016 | 371 | 0.110 |
Why?
|
Protein-Arginine N-Methyltransferases | 1 | 2013 | 129 | 0.100 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2015 | 249 | 0.100 |
Why?
|
Interleukin-6 | 2 | 2024 | 3230 | 0.100 |
Why?
|
Histocompatibility Antigens Class I | 2 | 2019 | 1362 | 0.100 |
Why?
|
Time Factors | 11 | 2021 | 40267 | 0.100 |
Why?
|
Risk Factors | 10 | 2022 | 74954 | 0.100 |
Why?
|
Hepatocyte Growth Factor | 1 | 2014 | 269 | 0.100 |
Why?
|
Back Pain | 1 | 2016 | 547 | 0.100 |
Why?
|
Genotype | 3 | 2017 | 13038 | 0.100 |
Why?
|
Digestive System | 1 | 2013 | 244 | 0.100 |
Why?
|
Neoplastic Stem Cells | 2 | 2017 | 1356 | 0.100 |
Why?
|
Coronavirus Infections | 2 | 2020 | 3118 | 0.100 |
Why?
|
Xenograft Model Antitumor Assays | 3 | 2018 | 3616 | 0.100 |
Why?
|
Arthritis | 1 | 2018 | 684 | 0.100 |
Why?
|
Sarcopenia | 1 | 2017 | 376 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2021 | 1598 | 0.100 |
Why?
|
Pneumonia, Viral | 2 | 2020 | 3241 | 0.100 |
Why?
|
Androstadienes | 1 | 2014 | 348 | 0.100 |
Why?
|
Intestine, Large | 1 | 2012 | 69 | 0.100 |
Why?
|
Deglutition Disorders | 2 | 2016 | 641 | 0.100 |
Why?
|
Glutarates | 1 | 2014 | 243 | 0.100 |
Why?
|
Affect | 1 | 2020 | 1501 | 0.100 |
Why?
|
Cyclin D1 | 1 | 2013 | 453 | 0.100 |
Why?
|
Young Adult | 12 | 2022 | 60048 | 0.090 |
Why?
|
Genes, ras | 1 | 2014 | 665 | 0.090 |
Why?
|
RNA-Binding Proteins | 1 | 2020 | 1883 | 0.090 |
Why?
|
Anti-Inflammatory Agents | 2 | 2018 | 1812 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2023 | 2256 | 0.090 |
Why?
|
Receptors, Cytoplasmic and Nuclear | 1 | 2015 | 861 | 0.090 |
Why?
|
Constriction, Pathologic | 1 | 2014 | 1104 | 0.090 |
Why?
|
Europe | 2 | 2015 | 3439 | 0.090 |
Why?
|
Morpholines | 1 | 2014 | 584 | 0.090 |
Why?
|
United States | 14 | 2023 | 73144 | 0.090 |
Why?
|
MAP Kinase Signaling System | 1 | 2018 | 1492 | 0.090 |
Why?
|
Actuarial Analysis | 1 | 2010 | 372 | 0.090 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 2 | 2014 | 388 | 0.090 |
Why?
|
Defecation | 1 | 2012 | 191 | 0.090 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2014 | 346 | 0.090 |
Why?
|
Age Factors | 5 | 2023 | 18472 | 0.090 |
Why?
|
Neoplasm Metastasis | 5 | 2020 | 4921 | 0.090 |
Why?
|
Terminology as Topic | 1 | 2017 | 1539 | 0.090 |
Why?
|
Sensory Receptor Cells | 1 | 2015 | 508 | 0.090 |
Why?
|
Prosthesis Implantation | 1 | 2015 | 594 | 0.090 |
Why?
|
Reproducibility of Results | 5 | 2021 | 20224 | 0.090 |
Why?
|
Biopsy | 3 | 2019 | 6808 | 0.090 |
Why?
|
Immunohistochemistry | 5 | 2019 | 11117 | 0.090 |
Why?
|
Pandemics | 2 | 2020 | 8750 | 0.090 |
Why?
|
Sexual Behavior | 1 | 2020 | 2200 | 0.080 |
Why?
|
Incidence | 6 | 2021 | 21544 | 0.080 |
Why?
|
Perioperative Care | 2 | 2018 | 1045 | 0.080 |
Why?
|
Duodenal Neoplasms | 1 | 2010 | 114 | 0.080 |
Why?
|
Heart Valve Prosthesis Implantation | 1 | 2000 | 1568 | 0.080 |
Why?
|
NF-kappa B | 1 | 2018 | 2487 | 0.080 |
Why?
|
Embolization, Therapeutic | 1 | 2019 | 1410 | 0.080 |
Why?
|
Gingiva | 2 | 2022 | 423 | 0.080 |
Why?
|
Uncertainty | 1 | 2014 | 759 | 0.080 |
Why?
|
Peripheral Nervous System Diseases | 1 | 2015 | 716 | 0.080 |
Why?
|
Semiconductors | 1 | 2009 | 98 | 0.080 |
Why?
|
Vagina | 1 | 2014 | 845 | 0.080 |
Why?
|
Bone Marrow | 2 | 2017 | 2929 | 0.080 |
Why?
|
Patient Care Team | 1 | 2020 | 2529 | 0.080 |
Why?
|
Failure to Thrive | 1 | 2009 | 140 | 0.080 |
Why?
|
Antibiotics, Antineoplastic | 1 | 2012 | 677 | 0.080 |
Why?
|
Crystallization | 1 | 2009 | 523 | 0.080 |
Why?
|
Carcinoma, Papillary | 1 | 2014 | 793 | 0.080 |
Why?
|
Membrane Proteins | 3 | 2014 | 7885 | 0.080 |
Why?
|
SEER Program | 4 | 2018 | 1474 | 0.080 |
Why?
|
Molecular Conformation | 1 | 2009 | 540 | 0.080 |
Why?
|
Lymphocyte Count | 2 | 2021 | 793 | 0.080 |
Why?
|
National Cancer Institute (U.S.) | 2 | 2020 | 300 | 0.080 |
Why?
|
Rats | 5 | 2018 | 23833 | 0.080 |
Why?
|
Cause of Death | 1 | 2019 | 3728 | 0.070 |
Why?
|
Simplexvirus | 2 | 1982 | 805 | 0.070 |
Why?
|
Cytarabine | 1 | 2010 | 697 | 0.070 |
Why?
|
Observer Variation | 1 | 2014 | 2623 | 0.070 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2019 | 4357 | 0.070 |
Why?
|
Drug Substitution | 1 | 2010 | 291 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 2 | 2022 | 459 | 0.070 |
Why?
|
Gastrointestinal Tract | 2 | 2010 | 839 | 0.070 |
Why?
|
Creatine Kinase, MB Form | 1 | 2008 | 202 | 0.070 |
Why?
|
Pain | 3 | 2013 | 5102 | 0.070 |
Why?
|
Prescriptions | 1 | 2010 | 388 | 0.070 |
Why?
|
Adolescent | 7 | 2023 | 89182 | 0.070 |
Why?
|
Medical Oncology | 3 | 2016 | 2348 | 0.070 |
Why?
|
Motion | 2 | 2011 | 789 | 0.070 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3666 | 0.070 |
Why?
|
Electrodes | 1 | 2009 | 617 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3412 | 0.070 |
Why?
|
Quinazolines | 1 | 2014 | 1374 | 0.070 |
Why?
|
Chordoma | 1 | 2010 | 349 | 0.070 |
Why?
|
Equipment Failure Analysis | 1 | 2009 | 848 | 0.070 |
Why?
|
Rats, Sprague-Dawley | 1 | 2018 | 8198 | 0.070 |
Why?
|
Surgery, Computer-Assisted | 1 | 2015 | 1006 | 0.070 |
Why?
|
Particle Accelerators | 2 | 2021 | 173 | 0.070 |
Why?
|
Skull Base Neoplasms | 1 | 2010 | 281 | 0.070 |
Why?
|
Forecasting | 1 | 2016 | 2948 | 0.070 |
Why?
|
Surface Properties | 1 | 2009 | 1166 | 0.070 |
Why?
|
Intraoperative Complications | 1 | 2013 | 1174 | 0.070 |
Why?
|
Hematologic Diseases | 1 | 2010 | 499 | 0.070 |
Why?
|
Cell Movement | 2 | 2020 | 5214 | 0.070 |
Why?
|
DNA Repair | 1 | 2016 | 2050 | 0.070 |
Why?
|
Nausea | 1 | 2009 | 682 | 0.070 |
Why?
|
Diagnosis, Differential | 3 | 2016 | 13019 | 0.070 |
Why?
|
Thoracic Neoplasms | 1 | 2008 | 269 | 0.070 |
Why?
|
MicroRNAs | 2 | 2020 | 3794 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2013 | 1094 | 0.070 |
Why?
|
Automation | 1 | 2008 | 588 | 0.070 |
Why?
|
Genetic Variation | 1 | 2001 | 6606 | 0.070 |
Why?
|
Vomiting | 1 | 2009 | 655 | 0.070 |
Why?
|
Materials Testing | 1 | 2009 | 872 | 0.060 |
Why?
|
Evidence-Based Medicine | 3 | 2015 | 3707 | 0.060 |
Why?
|
Mice | 10 | 2024 | 82004 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2005 | 5857 | 0.060 |
Why?
|
Recurrence | 2 | 2011 | 8501 | 0.060 |
Why?
|
Proteolipids | 1 | 2005 | 112 | 0.060 |
Why?
|
Abdomen | 1 | 2011 | 1136 | 0.060 |
Why?
|
Intraoperative Period | 2 | 2019 | 513 | 0.060 |
Why?
|
Laparoscopy | 1 | 2017 | 2034 | 0.060 |
Why?
|
Thymus Neoplasms | 1 | 2008 | 277 | 0.060 |
Why?
|
Postoperative Complications | 2 | 2020 | 15854 | 0.060 |
Why?
|
Particle Size | 1 | 2009 | 1653 | 0.060 |
Why?
|
Disease Management | 1 | 2016 | 2536 | 0.060 |
Why?
|
Colectomy | 1 | 2010 | 695 | 0.060 |
Why?
|
Surface-Active Agents | 1 | 2005 | 152 | 0.060 |
Why?
|
Protein Structure, Secondary | 2 | 2005 | 1216 | 0.060 |
Why?
|
Pulmonary Surfactants | 1 | 2005 | 169 | 0.060 |
Why?
|
Sickness Impact Profile | 1 | 2006 | 299 | 0.060 |
Why?
|
Geriatric Assessment | 1 | 2012 | 1422 | 0.060 |
Why?
|
Infratentorial Neoplasms | 1 | 2005 | 99 | 0.060 |
Why?
|
Analysis of Variance | 1 | 2013 | 6238 | 0.060 |
Why?
|
Delayed-Action Preparations | 1 | 2008 | 968 | 0.060 |
Why?
|
Predictive Value of Tests | 1 | 2021 | 15455 | 0.060 |
Why?
|
Protein Kinase Inhibitors | 2 | 2018 | 5707 | 0.060 |
Why?
|
Immobilization | 1 | 2005 | 230 | 0.060 |
Why?
|
Peptide Fragments | 3 | 2008 | 5151 | 0.060 |
Why?
|
Statistics, Nonparametric | 1 | 2009 | 2862 | 0.060 |
Why?
|
Gallium Radioisotopes | 1 | 2024 | 195 | 0.060 |
Why?
|
Lymphocytes | 2 | 2023 | 2610 | 0.060 |
Why?
|
Propensity Score | 2 | 2023 | 1955 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 106 | 0.050 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2014 | 2911 | 0.050 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2013 | 2889 | 0.050 |
Why?
|
Adenoma | 1 | 2014 | 2163 | 0.050 |
Why?
|
Coronary Vessels | 1 | 2014 | 3125 | 0.050 |
Why?
|
Mesenteric Veins | 1 | 2023 | 87 | 0.050 |
Why?
|
Troponin T | 1 | 2008 | 787 | 0.050 |
Why?
|
Comorbidity | 3 | 2018 | 10588 | 0.050 |
Why?
|
Ovarian Neoplasms | 1 | 2020 | 4908 | 0.050 |
Why?
|
Phosphorylation | 1 | 2014 | 8326 | 0.050 |
Why?
|
Cohort Studies | 7 | 2020 | 41791 | 0.050 |
Why?
|
Coronary Angiography | 1 | 2014 | 4537 | 0.050 |
Why?
|
RNA Viruses | 1 | 1983 | 111 | 0.050 |
Why?
|
Antimicrobial Cationic Peptides | 2 | 2001 | 353 | 0.050 |
Why?
|
Cell Proliferation | 2 | 2019 | 10464 | 0.050 |
Why?
|
Tooth Crown | 1 | 2022 | 61 | 0.050 |
Why?
|
Quality Control | 1 | 2005 | 833 | 0.050 |
Why?
|
Lung Injury | 1 | 2007 | 433 | 0.050 |
Why?
|
Islets of Langerhans | 1 | 2008 | 1349 | 0.050 |
Why?
|
Equipment Design | 1 | 2009 | 3529 | 0.050 |
Why?
|
Life Cycle Stages | 1 | 2022 | 161 | 0.050 |
Why?
|
Protein Precursors | 1 | 2005 | 1134 | 0.050 |
Why?
|
DNA-Binding Proteins | 2 | 2016 | 9618 | 0.050 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2005 | 876 | 0.050 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3781 | 0.050 |
Why?
|
Risk Assessment | 2 | 2015 | 24316 | 0.050 |
Why?
|
Nervous System Physiological Phenomena | 1 | 2022 | 115 | 0.050 |
Why?
|
Fractals | 1 | 2021 | 127 | 0.050 |
Why?
|
Incisor | 1 | 2022 | 173 | 0.050 |
Why?
|
Sequence Analysis | 1 | 2001 | 240 | 0.050 |
Why?
|
Guidelines as Topic | 2 | 2019 | 1397 | 0.050 |
Why?
|
S100 Proteins | 1 | 2001 | 217 | 0.050 |
Why?
|
Lamivudine | 1 | 2022 | 367 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2020 | 12092 | 0.040 |
Why?
|
Rotavirus Infections | 1 | 2001 | 85 | 0.040 |
Why?
|
Alveolar Process | 1 | 2022 | 295 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2018 | 10266 | 0.040 |
Why?
|
Genes, MHC Class I | 1 | 2021 | 236 | 0.040 |
Why?
|
Stereotaxic Techniques | 1 | 2002 | 556 | 0.040 |
Why?
|
Endothelial Growth Factors | 1 | 2022 | 674 | 0.040 |
Why?
|
Hematologic Tests | 1 | 2021 | 239 | 0.040 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2021 | 330 | 0.040 |
Why?
|
Ultrasonography | 2 | 2010 | 6001 | 0.040 |
Why?
|
Cranial Irradiation | 1 | 2002 | 395 | 0.040 |
Why?
|
Pyrimidine Nucleosides | 1 | 2019 | 7 | 0.040 |
Why?
|
Sensitivity and Specificity | 3 | 2022 | 14736 | 0.040 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 1751 | 0.040 |
Why?
|
Nuclear Proteins | 1 | 2014 | 5802 | 0.040 |
Why?
|
Blood Loss, Surgical | 1 | 2023 | 642 | 0.040 |
Why?
|
Cystectomy | 1 | 2023 | 645 | 0.040 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2021 | 640 | 0.040 |
Why?
|
Phantoms, Imaging | 1 | 2007 | 2528 | 0.040 |
Why?
|
Models, Theoretical | 2 | 2021 | 3579 | 0.040 |
Why?
|
Child, Preschool | 2 | 2016 | 42654 | 0.040 |
Why?
|
Biliary Tract Surgical Procedures | 1 | 2018 | 50 | 0.040 |
Why?
|
Therapeutic Uses | 1 | 2018 | 2 | 0.040 |
Why?
|
Amino Acid Sequence | 4 | 2005 | 13425 | 0.040 |
Why?
|
Interleukin-7 Receptor alpha Subunit | 1 | 2018 | 50 | 0.040 |
Why?
|
Interferons | 1 | 2022 | 717 | 0.040 |
Why?
|
Cell Survival | 2 | 2019 | 5792 | 0.040 |
Why?
|
Nasal Mucosa | 1 | 2001 | 411 | 0.040 |
Why?
|
Aspirin | 1 | 1990 | 3136 | 0.040 |
Why?
|
Videoconferencing | 1 | 2020 | 209 | 0.040 |
Why?
|
Sex Factors | 1 | 2012 | 10656 | 0.040 |
Why?
|
Smad4 Protein | 1 | 2019 | 193 | 0.040 |
Why?
|
Depression | 1 | 2017 | 8241 | 0.040 |
Why?
|
Linear Energy Transfer | 1 | 2018 | 154 | 0.040 |
Why?
|
Molecular Sequence Data | 4 | 2005 | 17626 | 0.040 |
Why?
|
Body Weight | 1 | 2008 | 4630 | 0.040 |
Why?
|
Cell Communication | 1 | 2024 | 1660 | 0.040 |
Why?
|
Fibrosis | 1 | 2024 | 2076 | 0.040 |
Why?
|
Barium | 1 | 2016 | 62 | 0.030 |
Why?
|
Lymphocyte Subsets | 1 | 2018 | 313 | 0.030 |
Why?
|
Lipids | 1 | 2008 | 3344 | 0.030 |
Why?
|
Interleukin-2 Receptor alpha Subunit | 1 | 2018 | 306 | 0.030 |
Why?
|
Pancreas | 1 | 2023 | 1701 | 0.030 |
Why?
|
Cytoplasm | 1 | 1981 | 1500 | 0.030 |
Why?
|
Cost-Benefit Analysis | 2 | 2020 | 5538 | 0.030 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2008 | 2044 | 0.030 |
Why?
|
Cesium Radioisotopes | 1 | 2016 | 38 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2020 | 365 | 0.030 |
Why?
|
HSP90 Heat-Shock Proteins | 1 | 2019 | 423 | 0.030 |
Why?
|
Cobalt Radioisotopes | 1 | 2016 | 75 | 0.030 |
Why?
|
Length of Stay | 1 | 2010 | 6516 | 0.030 |
Why?
|
Radiation | 1 | 2015 | 49 | 0.030 |
Why?
|
Organoids | 1 | 2022 | 746 | 0.030 |
Why?
|
Peptides | 2 | 2005 | 4352 | 0.030 |
Why?
|
Drugs, Chinese Herbal | 1 | 1997 | 147 | 0.030 |
Why?
|
Kidney | 2 | 2011 | 7063 | 0.030 |
Why?
|
Tumor Escape | 1 | 2019 | 372 | 0.030 |
Why?
|
Neoplasm Proteins | 2 | 2017 | 3609 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2020 | 1839 | 0.030 |
Why?
|
Postoperative Care | 2 | 2014 | 1479 | 0.030 |
Why?
|
Linear Models | 2 | 2016 | 5878 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1622 | 0.030 |
Why?
|
Autopsy | 1 | 2019 | 1013 | 0.030 |
Why?
|
Glioblastoma | 1 | 2011 | 3526 | 0.030 |
Why?
|
Severity of Illness Index | 2 | 2013 | 15939 | 0.030 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 782 | 0.030 |
Why?
|
Child | 3 | 2016 | 80894 | 0.030 |
Why?
|
Phenylurea Compounds | 1 | 2019 | 529 | 0.030 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2019 | 654 | 0.030 |
Why?
|
Rad51 Recombinase | 1 | 2016 | 191 | 0.030 |
Why?
|
Drug Repositioning | 1 | 2017 | 244 | 0.030 |
Why?
|
Mice, SCID | 1 | 2020 | 2632 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10776 | 0.030 |
Why?
|
Inhibitor of Apoptosis Proteins | 1 | 2015 | 199 | 0.030 |
Why?
|
Copper | 1 | 2017 | 369 | 0.030 |
Why?
|
Immunity | 1 | 2021 | 1003 | 0.030 |
Why?
|
Endodeoxyribonucleases | 1 | 2016 | 166 | 0.030 |
Why?
|
Japan | 1 | 2019 | 1418 | 0.030 |
Why?
|
Spiral Cone-Beam Computed Tomography | 1 | 2015 | 32 | 0.030 |
Why?
|
Colon, Ascending | 1 | 2014 | 14 | 0.030 |
Why?
|
Disease Models, Animal | 3 | 2018 | 18358 | 0.030 |
Why?
|
Clinical Protocols | 1 | 2020 | 1445 | 0.030 |
Why?
|
Protein Kinase C | 1 | 2019 | 1207 | 0.030 |
Why?
|
Stomach Diseases | 1 | 2015 | 134 | 0.030 |
Why?
|
Mitogen-Activated Protein Kinases | 1 | 2019 | 1246 | 0.030 |
Why?
|
Polyethylene Glycols | 1 | 2020 | 1195 | 0.030 |
Why?
|
Central Nervous System Neoplasms | 1 | 2002 | 930 | 0.030 |
Why?
|
Insulin Resistance | 1 | 2008 | 3981 | 0.030 |
Why?
|
Reference Standards | 1 | 2017 | 1013 | 0.030 |
Why?
|
Hydrazines | 1 | 2015 | 223 | 0.030 |
Why?
|
Clinical Trials as Topic | 2 | 2022 | 8051 | 0.030 |
Why?
|
Polyps | 1 | 2015 | 200 | 0.030 |
Why?
|
Vitelline Membrane | 1 | 1993 | 4 | 0.030 |
Why?
|
Antigen-Presenting Cells | 1 | 2017 | 962 | 0.030 |
Why?
|
MutS Homolog 2 Protein | 1 | 2014 | 200 | 0.030 |
Why?
|
Edema | 1 | 1997 | 766 | 0.030 |
Why?
|
Australia | 1 | 2017 | 1265 | 0.030 |
Why?
|
Herpesvirus 1, Human | 1 | 2019 | 744 | 0.030 |
Why?
|
Blood Glucose | 1 | 2008 | 6430 | 0.030 |
Why?
|
Cytodiagnosis | 1 | 2017 | 452 | 0.030 |
Why?
|
Advisory Committees | 1 | 2017 | 797 | 0.030 |
Why?
|
Databases, Factual | 2 | 2019 | 8072 | 0.030 |
Why?
|
Fanconi Anemia | 1 | 2016 | 327 | 0.030 |
Why?
|
Triage | 1 | 2020 | 994 | 0.030 |
Why?
|
Phthalazines | 1 | 2016 | 397 | 0.030 |
Why?
|
Pharmaceutical Preparations | 1 | 2021 | 1088 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2018 | 1260 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2018 | 4647 | 0.030 |
Why?
|
ROC Curve | 1 | 2021 | 3622 | 0.030 |
Why?
|
Random Allocation | 1 | 2017 | 2397 | 0.030 |
Why?
|
Pyrazines | 1 | 2019 | 1206 | 0.030 |
Why?
|
Single-Cell Analysis | 1 | 2024 | 2533 | 0.030 |
Why?
|
Anti-Bacterial Agents | 2 | 2001 | 7458 | 0.030 |
Why?
|
Infant | 2 | 2005 | 36512 | 0.030 |
Why?
|
Quality-Adjusted Life Years | 1 | 2019 | 1735 | 0.020 |
Why?
|
RNA | 1 | 2022 | 2726 | 0.020 |
Why?
|
DNA Repair Enzymes | 1 | 2014 | 346 | 0.020 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1905 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2013 | 551 | 0.020 |
Why?
|
Mesenteric Artery, Superior | 1 | 2011 | 96 | 0.020 |
Why?
|
Endosonography | 1 | 2015 | 622 | 0.020 |
Why?
|
Th17 Cells | 1 | 2018 | 791 | 0.020 |
Why?
|
Circular Dichroism | 2 | 2001 | 337 | 0.020 |
Why?
|
Body Burden | 1 | 2011 | 158 | 0.020 |
Why?
|
Cadherins | 1 | 2016 | 905 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2019 | 1999 | 0.020 |
Why?
|
Hospitalization | 1 | 2011 | 10844 | 0.020 |
Why?
|
DNA Mismatch Repair | 1 | 2014 | 433 | 0.020 |
Why?
|
Ions | 1 | 2011 | 256 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2007 | 9063 | 0.020 |
Why?
|
Analgesics | 1 | 1997 | 1070 | 0.020 |
Why?
|
Esophagus | 1 | 2016 | 1042 | 0.020 |
Why?
|
Guaiacol | 1 | 1990 | 5 | 0.020 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2013 | 1684 | 0.020 |
Why?
|
Herpesvirus 4, Human | 1 | 2016 | 1082 | 0.020 |
Why?
|
Triazoles | 1 | 2015 | 904 | 0.020 |
Why?
|
Adenosine Triphosphatases | 1 | 2014 | 842 | 0.020 |
Why?
|
Antiviral Agents | 1 | 2022 | 3064 | 0.020 |
Why?
|
Microscopy, Electron | 2 | 1983 | 2559 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 1105 | 0.020 |
Why?
|
Salicylates | 1 | 1990 | 128 | 0.020 |
Why?
|
Ankle Joint | 1 | 2013 | 451 | 0.020 |
Why?
|
Colonic Polyps | 1 | 2014 | 557 | 0.020 |
Why?
|
Inguinal Canal | 1 | 2008 | 71 | 0.020 |
Why?
|
China | 1 | 2015 | 2389 | 0.020 |
Why?
|
Spermatozoa | 1 | 1993 | 631 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3541 | 0.020 |
Why?
|
Killer Cells, Natural | 1 | 2018 | 2207 | 0.020 |
Why?
|
Mutation, Missense | 1 | 2018 | 2593 | 0.020 |
Why?
|
Radiography, Abdominal | 1 | 2011 | 541 | 0.020 |
Why?
|
DNA | 1 | 2022 | 7211 | 0.020 |
Why?
|
Antigens, CD | 1 | 1999 | 4031 | 0.020 |
Why?
|
Oocytes | 1 | 1993 | 1171 | 0.020 |
Why?
|
Ilium | 1 | 2008 | 155 | 0.020 |
Why?
|
Prosthesis Failure | 1 | 2013 | 1208 | 0.020 |
Why?
|
Neutrophils | 1 | 2021 | 3785 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 1999 | 3712 | 0.020 |
Why?
|
Lung | 1 | 2007 | 10087 | 0.020 |
Why?
|
Morphogenesis | 2 | 1982 | 747 | 0.020 |
Why?
|
Carbon | 1 | 2011 | 672 | 0.020 |
Why?
|
Genomics | 1 | 2023 | 5916 | 0.020 |
Why?
|
Cardiovascular Diseases | 1 | 2013 | 15652 | 0.020 |
Why?
|
Glioma | 1 | 2002 | 3526 | 0.020 |
Why?
|
Sequence Homology, Amino Acid | 2 | 2001 | 2750 | 0.020 |
Why?
|
Proteins | 1 | 2001 | 6006 | 0.020 |
Why?
|
Endoscopy, Digestive System | 1 | 2009 | 357 | 0.020 |
Why?
|
Organ Size | 1 | 2011 | 2268 | 0.020 |
Why?
|
Liver Cirrhosis | 1 | 2017 | 1957 | 0.020 |
Why?
|
Acute Disease | 1 | 2017 | 7242 | 0.020 |
Why?
|
Breast Neoplasms | 1 | 2013 | 21163 | 0.020 |
Why?
|
Blotting, Western | 1 | 2013 | 5033 | 0.020 |
Why?
|
Socioeconomic Factors | 1 | 2020 | 7861 | 0.020 |
Why?
|
Xerostomia | 1 | 2006 | 94 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5758 | 0.020 |
Why?
|
Spectroscopy, Fourier Transform Infrared | 1 | 2005 | 162 | 0.020 |
Why?
|
Tissue Distribution | 1 | 1990 | 2298 | 0.020 |
Why?
|
Osteoarthritis | 1 | 2013 | 1070 | 0.020 |
Why?
|
Likelihood Functions | 1 | 2008 | 993 | 0.020 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2018 | 4411 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2016 | 5898 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2013 | 3794 | 0.020 |
Why?
|
Piperazines | 1 | 2016 | 2552 | 0.020 |
Why?
|
Fertilization in Vitro | 1 | 1993 | 1302 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 2 | 2001 | 1955 | 0.010 |
Why?
|
Cell Nucleus | 1 | 2013 | 2887 | 0.010 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2010 | 1149 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2020 | 14481 | 0.010 |
Why?
|
Societies, Medical | 1 | 2016 | 3960 | 0.010 |
Why?
|
Gastrostomy | 1 | 2006 | 325 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2020 | 14783 | 0.010 |
Why?
|
Pain Measurement | 1 | 2013 | 3579 | 0.010 |
Why?
|
Small Cell Lung Carcinoma | 1 | 2008 | 450 | 0.010 |
Why?
|
Patient Readmission | 1 | 2017 | 3312 | 0.010 |
Why?
|
Reoperation | 1 | 2013 | 4340 | 0.010 |
Why?
|
Macrophages | 1 | 2018 | 5796 | 0.010 |
Why?
|
Intestines | 1 | 2011 | 1911 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2014 | 5800 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2018 | 19019 | 0.010 |
Why?
|
Spectrophotometry, Atomic | 1 | 2001 | 80 | 0.010 |
Why?
|
Androgen Antagonists | 1 | 2010 | 1421 | 0.010 |
Why?
|
Electronic Health Records | 1 | 2019 | 4874 | 0.010 |
Why?
|
Reference Values | 1 | 2009 | 4941 | 0.010 |
Why?
|
Gastroesophageal Reflux | 1 | 2009 | 835 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2008 | 3438 | 0.010 |
Why?
|
Cathelicidins | 1 | 2001 | 81 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2015 | 4076 | 0.010 |
Why?
|
Staphylococcus epidermidis | 1 | 2001 | 121 | 0.010 |
Why?
|
Regression Analysis | 1 | 2010 | 6350 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3236 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16716 | 0.010 |
Why?
|
Immunoenzyme Techniques | 1 | 1983 | 1705 | 0.010 |
Why?
|
Medicare | 1 | 2019 | 6881 | 0.010 |
Why?
|
Cell Differentiation | 1 | 2018 | 11659 | 0.010 |
Why?
|
Logistic Models | 1 | 2014 | 13323 | 0.010 |
Why?
|
DNA Methylation | 1 | 2014 | 4419 | 0.010 |
Why?
|
Listeria monocytogenes | 1 | 2001 | 246 | 0.010 |
Why?
|
Ferritins | 1 | 1982 | 601 | 0.010 |
Why?
|
Kangai-1 Protein | 1 | 1999 | 22 | 0.010 |
Why?
|
Escherichia coli | 2 | 2001 | 4209 | 0.010 |
Why?
|
Body Mass Index | 1 | 2017 | 13050 | 0.010 |
Why?
|
Virion | 1 | 1981 | 430 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2017 | 22355 | 0.010 |
Why?
|
Hearing Loss | 1 | 2006 | 786 | 0.010 |
Why?
|
Decision Making | 1 | 2012 | 3953 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2001 | 1992 | 0.010 |
Why?
|
Otitis | 1 | 1997 | 21 | 0.010 |
Why?
|
Glucosephosphate Dehydrogenase Deficiency | 1 | 1978 | 95 | 0.010 |
Why?
|
Liposomes | 1 | 2001 | 792 | 0.010 |
Why?
|
Tablets | 1 | 1997 | 149 | 0.010 |
Why?
|
Zinc | 1 | 2001 | 677 | 0.010 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1978 | 239 | 0.010 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2001 | 2487 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2011 | 4339 | 0.010 |
Why?
|
Dexamethasone | 1 | 2002 | 1965 | 0.010 |
Why?
|
HeLa Cells | 1 | 1981 | 3092 | 0.010 |
Why?
|
Macaca mulatta | 1 | 2001 | 2361 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2001 | 3779 | 0.010 |
Why?
|
Weight Loss | 1 | 2006 | 2715 | 0.010 |
Why?
|
Capillary Permeability | 1 | 1997 | 773 | 0.010 |
Why?
|
Lipopolysaccharides | 1 | 2001 | 2215 | 0.010 |
Why?
|
Zona Pellucida | 1 | 1993 | 15 | 0.010 |
Why?
|
Sperm-Ovum Interactions | 1 | 1993 | 24 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 18047 | 0.010 |
Why?
|
Protein Conformation | 1 | 2001 | 3957 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1997 | 1890 | 0.010 |
Why?
|
Mesocricetus | 1 | 1993 | 256 | 0.010 |
Why?
|
Glucocorticoids | 1 | 2002 | 2168 | 0.010 |
Why?
|
Microinjections | 1 | 1993 | 323 | 0.010 |
Why?
|
Drug Combinations | 1 | 1997 | 2078 | 0.010 |
Why?
|
Extracellular Space | 1 | 1993 | 565 | 0.010 |
Why?
|
Base Sequence | 1 | 2001 | 12421 | 0.010 |
Why?
|
Cricetinae | 1 | 1993 | 2423 | 0.010 |
Why?
|
Diet | 1 | 2006 | 8097 | 0.000 |
Why?
|
Cell Line | 1 | 1981 | 15593 | 0.000 |
Why?
|
Methods | 1 | 1978 | 1067 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1978 | 1629 | 0.000 |
Why?
|
Infant, Newborn | 1 | 1978 | 26410 | 0.000 |
Why?
|